Nuvectis Pharma annual shares outstanding
2021
2022
2023
2024
2025
Nuvectis Pharma Shares Outstanding History (NVCT)
Nuvectis Pharma reported 25.7M shares outstanding at the end of fiscal 2025.
View full Nuvectis Pharma company overviewNuvectis Pharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 25.7M | 6.2M | +31.71% |
| 2024 | 2024-12-31 | 19.5M | 2.1M | +11.92% |
| 2023 | 2023-12-31 | 17.4M | 2.2M | +14.67% |
| 2022 | 2022-12-31 | 15.2M | 10.7M | +237.16% |
| 2021 | 2021-12-31 | 4.5M | — | — |
Nuvectis Pharma quarterly shares outstanding
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 26.7M | 2.8M | +11.80% |
| Q1 2026 | 2026-03-31 | 26.5M | 2.9M | +12.23% |
| Q4 2025 | 2025-12-31 | 25.7M | 6.2M | +31.71% |
| Q3 2025 | 2025-09-30 | 25.6M | 6.7M | +35.05% |
| Q2 2025 | 2025-06-30 | 23.9M | 5.1M | +27.36% |
| Q1 2025 | 2025-03-31 | 23.6M | 5.3M | +28.76% |
| Q4 2024 | 2024-12-31 | 19.5M | 2.1M | +11.92% |
| Q3 2024 | 2024-09-30 | 19.0M | 1.7M | +9.68% |
| Q2 2024 | 2024-06-30 | 18.7M | 1.5M | +8.87% |
| Q1 2024 | 2024-03-31 | 18.4M | 2.3M | +14.67% |
| Q4 2023 | 2023-12-31 | 17.4M | 2.2M | +14.67% |
| Q3 2023 | 2023-09-30 | 17.3M | 2.7M | +18.22% |
| Q2 2023 | 2023-06-30 | 17.2M | 4.5M | +35.41% |
| Q1 2023 | 2023-03-31 | 16.0M | 3.3M | +25.87% |
| Q4 2022 | 2022-12-31 | 15.2M | 10.7M | +237.16% |
| Q3 2022 | 2022-09-30 | 14.6M | — | — |
| Q2 2022 | 2022-06-30 | 12.7M | — | — |
| Q1 2022 | 2022-03-31 | 12.7M | — | — |
| Q4 2021 | 2021-12-31 | 4.5M | — | — |
Nuvectis Pharma shares outstanding trends
Between the periods ended 2021-12-31 and 2025-12-31, Nuvectis Pharma's shares outstanding moved from 4.5M to 25.7M, a change of 21.2M. The latest reported quarter, Q2 2026, shows 26.7M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvectis Pharma source filings ↗Community posts
Nuvectis’ partner reports expanded glioma responses for experimental BRAF inhibitor
Nuvectis ($NVCT) reported expanded Phase 1b results for NXP200 from partner Haisco’s Chinese study in recurrent or progressive BRAF V600-mutated glioma. Tumor responses occurred in eight of twenty evaluable patients with high-grade disease ...
